Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, life-threating inflammatory-fibrotic diseases. The Company's lead product candidate, Resunab, is an oral anti-inflammatory drug that is being developed for the treatment of inflammatory disorders, such as cystic fibrosis (CF) and scleroderma. The Company has completed the Phase I safety studies for the treatment of scleroderma and cystic fibrosis. The Company has submitted an Investigational New Drug Application (INDA) to the United States Food and Drug Administration (FDA) for a Phase IIa double-blind placebo controlled clinical study evaluating Resunab in patients with diffuse scleroderma. Pre-clinical and Phase I clinical studies (123 subjects) have shown Resunab to have a favorable safety profile coupled with suitable potency in pre-clinical models of inflammation and fibrosis.